SLC5A2 and hydrops fetalis: Notably, recent pooled analyses from DELIVER and EMPEROR-Preserved trials confirmed the efficacy of SGLT2 inhibitors across a broad ejection fraction range, highlighting the clinical relevance of vascular and metabolic mechanisms in HF therapy [1,2,40,73,74,75,76,77].